Design and Implementation of an Anti–Factor Xa Heparin Monitoring Protocol
- 11 June 2020
- journal article
- research article
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 31 (2), 129-137
- https://doi.org/10.4037/aacnacc2020132
Abstract
The VA Northeast Ohio Healthcare System introduced a new nurse-driven anti–factor Xa (anti-Xa) protocol for monitoring unfractionated heparin to replace the previous activated partial thromboplastin time protocol. To design, implement, and evaluate the efficacy of the anti-Xa monitoring protocol. An interdisciplinary team of providers collaborated to develop and implement a nurse-driven, facility-wide anti–factor Xa protocol for monitoring unfractionated heparin therapy. The effectiveness of this protocol was evaluated by retrospective analysis. We reviewed 100 medical records for compliance with the new anti-Xa monitoring protocol. We then evaluated 178 patients whose anticoagulation was monitored with the anti-Xa assay to determine the time to therapeutic range. We found that 80% of patients receiving the anti-Xa protocol achieved therapeutic anticoagulation within 24 hours, as compared with 54% of patients receiving the activated partial thromboplastin time protocol (P < .001). Protocol conversion also yielded a decrease in blood draws, dose adjustments, and potential calculation errors. Monitoring intravenous heparin therapy with the anti-Xa assay rather than activated partial thromboplastin time resulted in a shorter time to therapeutic anticoagulation, longer maintenance of therapeutic levels, and fewer laboratory tests and heparin dosage changes. We believe the current practice of monitoring heparin treatment with activated partial thromboplastin time assays should be reexamined.Keywords
This publication has 15 references indexed in Scilit:
- Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoringAmerican Journal of Health-System Pharmacy, 2015
- A Comparative Trial of Anti-Factor Xa Levels Versus the Activated Partial Thromboplastin Time for Heparin MonitoringHospital Practice, 2013
- Activated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin MonitoringAmerican Journal of Clinical Pathology, 2013
- Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated with Intravenous Unfractionated HeparinAnnals of Pharmacotherapy, 2013
- Activated Partial Thromboplastin Time Versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous InfusionAnnals of Pharmacotherapy, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsJournal of the American College of Cardiology, 2011
- Nurse-Driven Intravenous Heparin ProtocolAACN Advanced Critical Care, 2010
- Problems In Laboratory Monitoring Of Heparin DosageBritish Journal of Haematology, 2000
- Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and SafetySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1995
- The anticoagulant activity of heparin: Measurement and relationship to chemical structureJournal of Pharmaceutical and Biomedical Analysis, 1989